First Clinical Trial of Pig Kidney Transplants Underway at NYU Langone Health

United Therapeutics has initiated the first clinical trial of pig kidney transplants at NYU Langone Health, exploring the potential of xenotransplantation to save lives. The trial will initially involve six participants, with plans for expansion if successful.

The initial clinical trial to assess the viability of transplanting pig kidneys into humans has commenced. United Therapeutics, a company specialising in gene-edited pig kidneys, announced that the first transplant was successfully conducted at NYU Langone Health. This marks a significant step in the exploration of animal-to-human transplants. Another US company, eGenesis, is also preparing to start its own pig kidney clinical trial soon.

These trials are pioneering efforts in xenotransplantation. To maintain participant confidentiality, details about the timing of the NYU surgery and patient information are not being disclosed. Dr. Robert Montgomery from NYU, who led the transplant team, mentioned that there is a list of patients interested in participating in this small trial. Initially, six people will be included, with potential expansion to 50 as more centres join.

FDA Approval and Previous Experiments

The Food and Drug Administration (FDA) has approved these studies following a series of "compassionate use" experiments with varied outcomes. The initial gene-edited pig kidney transplants were not long-lasting. Subsequently, doctors began working with patients who urgently needed kidneys but were not as critically ill as previous recipients.

At NYU, an Alabama woman's pig kidney functioned for 130 days before she returned to dialysis. A New Hampshire man set the latest record with a pig kidney lasting 271 days at Massachusetts General Hospital; however, he is back on dialysis after the organ's decline and removal last month. Another patient at Mass General and a woman in China are known to be living with pig kidneys.

Advancements in Gene Editing

Scientists are genetically modifying pigs to make their organs more compatible with humans, aiming to reduce immediate immune rejection. United Therapeutics' trial involves pig kidneys with 10 gene edits. These edits remove pig genes that cause early rejection and excessive organ growth while adding human genes to enhance compatibility.

Dr. Montgomery expressed optimism about the progress, stating, "This thing is moving in the right direction as doctors learn from each patient's experience." He highlighted that the option to resume dialysis provides a safety net for patients.

Addressing Organ Shortages

In the US, over 100,000 individuals are on the transplant waiting list, most needing kidneys. Thousands die each year while waiting for an organ. The potential of xenotransplantation offers hope as an alternative solution to this shortage.

The ongoing trials represent a crucial development in medical science as researchers strive to refine techniques and improve outcomes for patients requiring transplants.

With inputs from PTI